Literature DB >> 15883751

Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model.

Amal K Bose1, Mihaela M Mocanu, Richard D Carr, Derek M Yellon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15883751     DOI： 10.1007/s10557-005-6892-4

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN： 0920-3206            Impact factor:   3.727


× No keyword cloud information.
  43 in total

Review 1.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

Review 2.  Cardiovascular effects of antiobesity drugs: are the new medicines all the same?

Authors:  Mauro Cataldi; Angelo Cignarelli; Francesco Giallauria; Giovanna Muscogiuri; Luigi Barrea; Silvia Savastano; Annamaria Colao
Journal:  Int J Obes Suppl       Date:  2020-07-20

3.  Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.

Authors:  Jamie E Mells; Ping P Fu; Shvetank Sharma; Darin Olson; Lihong Cheng; Jeffrey A Handy; Neeraj K Saxena; Dan Sorescu; Frank A Anania
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-10-28       Impact factor: 4.052

4.  Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow.

Authors:  Steven P Moberly; Zachary C Berwick; Meredith Kohr; Mark Svendsen; Kieren J Mather; Johnathan D Tune
Journal:  Exp Biol Med (Maywood)       Date:  2012-02-16

Review 5.  The effect of glucagon-like peptide 1 on cardiovascular risk.

Authors:  Jacob Sivertsen; Jaya Rosenmeier; Jens J Holst; Tina Vilsbøll
Journal:  Nat Rev Cardiol       Date:  2012-01-31       Impact factor: 32.419

6.  Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart.

Authors:  Suzanne B Brown; Joseph R Libonati; Mary A Selak; Richard P Shannon; Rebecca A Simmons
Journal:  Cardiovasc Drugs Ther       Date:  2010-06       Impact factor: 3.727

7.  Saxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated Cardiomyopathy.

Authors:  Arpita Kalla Vyas; Lauren B Aerni-Flessner; Maria A Payne; Attila Kovacs; Patrick Y Jay; Paul W Hruz
Journal:  Cardiovasc Endocrinol       Date:  2012-12

Review 8.  Impact of hypoglycemic agents on myocardial ischemic preconditioning.

Authors:  Rosa Maria Rahmi Garcia; Paulo Cury Rezende; Whady Hueb
Journal:  World J Diabetes       Date:  2014-06-15

9.  GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

Authors:  Mohammad Hossein Noyan-Ashraf; M Abdul Momen; Kiwon Ban; Al-Muktafi Sadi; Yu-Qing Zhou; Ali M Riazi; Laurie L Baggio; R Mark Henkelman; Mansoor Husain; Daniel J Drucker
Journal:  Diabetes       Date:  2009-01-16       Impact factor: 9.461

10.  Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model.

Authors:  Jens Kristensen; Ulrik M Mortensen; Morten Schmidt; Peter Haubjerg Nielsen; Torsten Toftegaard Nielsen; Michael Maeng
Journal:  BMC Cardiovasc Disord       Date:  2009-07-23       Impact factor: 2.298
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.